MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 105, Issue 3, 2011, Pages 392-401

  Bernstein, Jonathan A ^a   Liu, Nancy ^b   Knorr, Barbara A ^b   Smugar, Steven S ^b   Hanley, William D ^b   Reiss, Theodore F ^b,c   Greenberg, Steven ^b  

^a Bernstein Clinical Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c 206 Carnegie Center   (United States)

Author keywords

5 Lipoxygenase; Chronic obstructive pulmonary disease; Forced expiratory volume in 1 s; Lung function

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; PLACEBO; SETILEUTON;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPOXEMIA; ILEUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; URINE RETENTION;

ADULT; AGED; ANALYSIS OF VARIANCE; BENZENESULFONATES; BENZOPYRANS; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; TREATMENT OUTCOME;

EID: 79151482943     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.09.021     Document Type: Article

References (24)

1. The global burden of disease update 2008 2004 World Health Organization
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2009 Global Initiative for Chronic Obstructive Lung Disease
3. J.C. Hogg, F. Chu, and S. Utokaparch The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653
4. A.P. Sampson FLAP inhibitors for the treatment of inflammatory diseases Curr Opin Investig Drugs 10 2009 1163 1172
5. K.M. Beeh, J. Beier, O. Kornmann, and R. Buhl Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis Sarcoidosis Vasc Diffuse Lung Dis 20 2003 138 143
6. E. Lee, T. Lindo, and N. Jackson Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors Am J Respir Crit Care Med 160 1999 2079 2085
7. J.S. Seggev, W.H. Thornton Jr., and T.E. Edes Serum leukotriene B4 levels in patients with obstructive pulmonary disease Chest 99 1991 289 291
8. M. Profita, R.D. Giorgi, and A. Sala Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Allergy 60 2005 1361 1369
9. P. Montuschi, S.A. Kharitonov, G. Ciabattoni, and P.J. Barnes Exhaled leukotrienes and prostaglandins in COPD Thorax 58 2003 585 588
10. S. Gompertz, and R.A. Stockley A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD Chest 122 2002 289 294
11. S.W. Crooks, D.L. Bayley, S.L. Hill, and R.A. Stockley Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4 Eur Respir J 15 2000 274 280
12. W. Berger, M.T. De Chandt, and C.B. Cairns Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease Int J Clin Pract 61 2007 663 676
13. L. Gronke, K.M. Beeh, and R. Cameron Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease Pulm Pharmacol Ther 21 2008 409 417
14. J.E. Williams, S.J. Singh, L. Sewell, G.H. Guyatt, and M.D. Morgan Development of a self-reported chronic respiratory questionnaire (CRQ-SR) Thorax 56 2001 954 959
15. H.J. Schunemann, L. Griffith, and R. Jaeschke A comparison of the original chronic respiratory questionnaire with a standardized version Chest 124 2003 1421 1429
16. R.G. Price Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications Eur J Clin Chem Clin Biochem 30 1992 693 705
17. O. Miettinen, and M. Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226
18. S. Appleton, P. Poole, B. Smith, A. Veale, and A. Bara Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation Cochrane Database Syst Rev 2002 CD001104
19. M. Miravitlles, J. Molina, K. Naberan, J.M. Cots, F. Ros, and C. Llor Factors determining the quality of life of patients with COPD in primary care Ther Adv Respir Dis 1 2007 85 92
20. A. Bhowmik, K. Chahal, G. Austin, and I. Chakravorty Improving mucociliary clearance in chronic obstructive pulmonary disease Respir Med 103 2009 496 502
21. J.B. Usery, T.H. Self, M.P. Muthiah, and C.K. Finch Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease Pharmacotherapy 28 2008 1183 1187
22. M. Cazzola, B. Boveri, and P. Carlucci Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist Pulm Pharmacol Ther 13 2000 301 305
23. P. Celik, A. Sakar, Y. Havlucu, H. Yuksel, P. Turkdogan, and A. Yorgancioglu Short-term effects of montelukast in stable patients with moderate to severe COPD Respir Med 99 2005 444 450
24. R.A. Pauwels, and K.F. Rabe Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet 364 2004 613 620